Back to Newsroom

StemCells, Inc. Provides Update on Its Phase I/II Study in Spinal Cord Injury

Significant Sensory Gains Observed in Additional Patients

NEWARK, Calif., May 19, 2014 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) announced today that Armin Curt, M.D., study principal investigator, presented an interim update on the Phase I/II trial in spinal cord injury at the Annual Meeting of the American Spinal Injury Association in San Antonio, Texas. Interim analysis of clinical data to date has shown that the significant post-transplant gains in sensory function first reported in two patients have now been observed in two additional patients.

Click here to read more